header logo image

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

December 5th, 2023 2:51 am

- Pre-NDA Meeting to discuss requirements for a 505(b)(2) NDA submission for IkT-001Pro in up to eight blood and stomach cancer indications -

Read more:
Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Related Post

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick